Bausch Health Statistics

Bausch Health Statistics and Facts

Bausch Health Inc

Pharmaceutical Industry/Brands

  • Type of Business


  • Establishment Year


  • Headquarters

    Laval, Canada

  • CEO and Key People

    Thomas J. Appio (CEO), Tom Vadaketh (CFO), Seana Carson (General Counsel), Mirza Dautbegovic (COO), Kathleen Fitzpatrick (Chief Human Resources Officer), Dr. Tage Ramakrishna, M.D. (Chief Medical Officer, President, R and D), and other key peoples.

  • Number of Employees

    Approximately 19,600 (2021)

  • Industry


  • Revenue

    US$ 8,434 million (2021)

  • Products

    Gastrointestinal, Dermatology Products, Aesthetic devices, International Pharmaceuticals, Generic, Neurology and others, Dentistry, Vision Care, and US Product List.

  • Subsidiaries

    Bausch+Lomb, Valeant Pharmaceuticals, ECR Pharmaceuticals Co. Inc., Coria Laboratories Ltd., Solta Medical International Inc., Salix Pharmaceuticals, ICN Polfa Rzeszow SA, Laboratorios Grossman SA, Amarin Pharmaceuticals Inc., Logistica Valeant S.A. de C.V, and other subsidiaries.

  • Competitors

    Amneal Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Medochemie Ltd, Endo, Shionogi & Company Limited, Dr. Reddy's Laboratories, Dexcel Pharma, Lannett Co. Inc., and other competitors.

  • Website

Bausch Health Statistics: Bausch Health Companies Inc. is a global business whose mission is to improve people’s lives by providing health care products. They are a global company that develops, manufactures, and markets, primarily in the therapeutic area of eye-health, dermatology, and gastroenterology (“GI”), a wide range of branded pharmaceuticals, branded generic and generic pharmaceuticals, over-the-counter, and medical devices such as contact lenses and intraocular lenses, which are marketed in around 100 countries.

The Bausch + Lomb Segment consists of global sales for Bausch + Lomb Vision Care products, Ophthalmic Pharmaceuticals, and Surgical products. Sales in the U.S. for GI products make up the Salix segment. International Rx is the segment that includes sales outside the U.S. and Puerto Rico of branded generic pharmaceutical, OTC, and branded pharmaceutical products. Ortho Dermatologic consists of sales in the U.S.A of Ortho Dermatologic products (dermatological) and sales of Solta aesthetic medicine devices. Diversified Product is a segment that includes sales in the U.S. of drugs in neurology, certain other therapeutic areas, generics, and dentistry products.


Commercial Location:

The U.S., Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, Greece, Hungary, Kazakhstan, Lithuania, Malaysia, Mexico, Montenegro, Peru, Poland, Russia, Serbia, Slovakia, Slovenia, and Ukraine

Manufacturing Facility:

The U.S., Brazil, Canada, Colombia, Germany, Ireland, Mexico, Poland, Serbia, and UAE


Bausch Health’s mission has five pillars. These are the guiding principles that underpin the company’s success and future growth. They are the company’s overall direction and provide the tools needed to meet any challenge.

  • Quality Healthcare Outcomes: The goal is to provide high-quality, meaningful services and products that resonate with patients as well as prescribers. Everything the company does is about delivering safe, effective products and bringing value to the stakeholders.
  • Customer-Oriented: Bausch’s actions and themselves are viewed through the eyes of their patients and customers. The company establishes strong relationships with customers and delivers quality products.
  • Innovation: Innovation is crucial. Bausch constantly looks for new ways and identifies opportunities to develop and advance creative, ethical, and timely solutions that are effective and timely.
  • Efficiency: Focusing on execution and efficiency enables in order to drive productivity. This allows them to identify where the company can make improvements and delivers value. The company responds quickly to the needs of changing markets and doesn’t compromise on quality.
  • People: Each day, Bausch’s employees arrive at work with a goal to improve people’s lives. They are crucial to the organization’s success. High-value work is done to develop and retain strong teams by rewarding excellence and creating opportunities for growth.


Bausch Health Inc.’s core values guide how to behave with others, including customers, vendors, colleagues, and shareholders. These are core values:

  • Accountability: Taking personal responsibility for all the actions and focusing only on delivering solutions.
  • Agility: Responding quickly to changes in both the internal and exterior environment without losing momentum.
  • Courage: Leading boldly, acting decisively, and envisioning new possibilities for the future.
  • Integrity: Conducting a business with the highest standards in professional conduct and ethics. Transparency, honesty, ethics, fairness, and integrity are the hallmarks of all of the interactions.
  • Teamwork: Toward common goals through honest and open communication. The company is open to each other’s ideas and shows concern.
  • Results-Oriented: Consistently delivering the required business results, meeting deadlines, complying with quality and productivity standards, and meeting all other requirements.

Business Strategy

Bausch Health Inc.’s strategy is to focus its business on core therapeutic areas and geographies with attractive growth opportunities. The company’s chosen therapeutic classes include durable products that Bausch feels have high operating margins and growth potential. This strategy has simplified their operations and increased the value of the eye-health, GI and dermatology businesses which together make up a large portion of the company’s revenue. Bausch believes that each of these businesses offers significant opportunities. They believe that their current portfolio, commercial footprint, pipeline of product development projects, and existing portfolio position us to be successful in these markets, which will allow them to maximize their potential to create shareholder value.

While they prepare for the separations of eye health, medical device aesthetics, and optical businesses, they keep their eyes on expanding and deepening the geographic reach of all of Bausch’s businesses. While continuing to explore new markets, they are also examining existing territories where their pharmaceuticals could be of benefit. The company is currently preparing to separate the Bausch + Lomb & Solta Medical businesses.

Bausch believes that its diverse product portfolio provides them with a stable revenue stream to support its operations. The ability to constantly refresh its pipeline and introduce new product solutions to markets that meet changing demand and replace those products that are no longer in favor is key to the company’s continued success. They also believe that their robust pipeline will allow them to not only bring the next generation of existing products to market but also to provide new and innovative solutions.

Bausch has refocused R&D to develop programs that they believe will lead to growth in the company’s core business, as well as create efficiencies in R&D costs and efforts. While they rely on R&D to create and update their product portfolios, simultaneously they also seek out co-promotions, licensing deals, and strategic acquisitions to increase their commercial footprint. The company strategically aligns itself with innovative product solutions that, when combined with its existing product offerings, address specific market needs.

Research and Development

Bausch Health Inc.’s R&D organization focuses on product development through clinical trials. Current R&D costs for 2021, 2020, and 2019 were approximately $465 million, respectively, $452 million and $471 million. R&D as a percentage of revenue was approximately 6% in 2020 and 2021, compared to 5% in 2019. The company’s portfolio has been rebalanced to better align with its long-term plans and keep the focus on its core business. Bausch invests in R&D to ensure organic growth. Their strategy is built on the internal development and marketing of new products. They continue to search for additional opportunities, including co-promotions.




Bausch Health Inc. Net Income

This chart shows the Bausch Health Inc. net income over the period 2012-2021. Bausch Health Inc. lost 116 million U.S. dollars in 2012 and 937 million U.S. Dollars in 2021.

Bausch Health Inc. Revenue, by Segment

This statistic shows Bausch Health Inc.’s revenue from 2017 through 2021. The data is divided by segment. In 2021, Ortho Dermatologic generated revenue of 564 million U.S. dollars.

Bausch Health Inc. Revenues of Top Diversified Products

This statistic shows the U.S. revenues for top diversified Bausch Health Inc. products in 2021. In 2021, Wellbutrin’s top product was worth 254 million U.S. dollars.

Bausch Health Inc. Total Assets

This statistic shows the history of Bausch Health Inc.’s total assets between 2011 and 2021. Bausch Health Inc. had total assets worth 13,050 million U.S. dollars in 2011 and 29,202 million U.S. dollars in 2021.

Bausch Health Inc. Total Operating Expense

This chart shows Bausch Health Inc.’s total operating costs from 2013 to 2021. Bausch Health Inc.’s total operating expenses were 6,179 million U.S. dollars in 2013 and 7,984 million U.S. dollars in 2021.

Bausch Health Inc. R&D Expenditure

This statistic shows Bausch Health Inc.’s research and development expenditures from 2013 to 2021. Bausch Health Inc. spent 157 million U.S. dollars on R&D in 2013 and 465 million U.S. dollars in 2021.


Goodwill is an asset that is acquired with the purchase of a business. It is defined as the difference in the acquisition date fair price of the consideration transferred and values assigned to assets acquired and liabilities assumed. Goodwill cannot be amortized. However, it is evaluated for impairment annually at the reporting unit’s level at least once per year. Goodwill impairment is defined as the amount that a reporting unit’s fair value exceeds its carrying value. A reporting unit is equal to or one level below an operating segment. An entity can first evaluate qualitatively whether it’s necessary to conduct quantitative impairment testing for any of its report units. If the Company believes that a reporting unit’s fair value is less than its carrying amount, then the quantitative impairment test must be performed. When determining whether a reporting unit’s fair value is less than its carrying value, the Company considers all relevant events and circumstances.

In the event of events that might indicate impairment, an interim impairment test for goodwill may be required. A significant decrease in Company market capitalization, changes within reportable segments, or unanticipated competitors could indicate that an interim impairment test might be necessary. The Company monitors its share price changes between annual impairment testing. The Company believes that a drop in its share value due to general market conditions is less indicative of goodwill impairment than a unilateral fall in its share. This would include any decline in its share pricing that reflects adverse changes in its operating performance, cash flow, and/or liquidity. If the Company’s market cap falls below its book value it will take into account, the duration and severity of the decline as well as the reasons for the decline to determine whether goodwill impairment has occurred. The Company believes short-term fluctuations of share prices might not always reflect underlying values.

Recent Developments:


  • Bausch Health, Bausch + Lomb, and Clearside Biomedical Inc. received FDA approval for XIPERE in June to treat patients with serious back-of-the-eye diseases.
  • In July, Bausch + Lomb, a Bausch Health subsidiary, announced the US launch of Biotrue Hydro Boost Lubricant Eye Drops, and Biotrue Microellar Eyelid Cleansing Wipes.
  • Bausch + Lomb, Bausch’s subsidiary, announced plans to invest EUR 90 million in expanding manufacturing operations at its Waterford facility.
  • Bausch and a few of its associates closed the August sale of Amoun Pharmaceutical Company S.A.E.’s stake to ADQ.
  • In October, the US FDA approved XIPERE by the company for the treatment of macular edema related to uveitis.
  • In December, JUBLIA, Topical Solution was awarded the American Podiatric Medical Association’s Seal of Approval. It is used to treat onychomycosis.
  • ClearVisc’s dispersive ophthalmic viscosurgical device (OVD), received approval from the US FDA in April.
  • VYZULTA was approved by the Ministry of Food and Drug Safety of South Korea in February.


  • In July, Bausch’s subsidiary Bausch + Lomb announced to expand its manufacturing facility in Virginia, the US.
  • In September, Bausch entered into an agreement to acquire all ophthalmology assets of Allegro Ophthalmics LLC.
  • In October, Bausch Health company entered into an agreement with Brien Holden Vision Institute, an Australian not-for-profit organization for a myopia control contact lens.
  • In August, the company announced its plans to spin off its eye care unit, Bausch + Lomb.

Share This Statistics


Cardinal Health Statistics and Facts


Teva Pharmaceutical Statistics and Facts